Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 6/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 16/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.47 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.47 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.47 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11980080 | 0.94 | MTOR (0.51) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1359235 | 0.92 | MTOR (0.61) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| Hydrochloric Acid SCHEMBL1360360 | 0.91 | MTOR (0.60) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL11980037 | 0.90 | MTOR (0.56) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1359843 | 0.90 | MTOR (0.55) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL7914530 | 0.88 | PIK3CA (0.56) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL11980079 | 0.88 | PIK3CA (0.59) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL11980078 | 0.88 | PIK3CA (0.59) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL7916075 | 0.87 | PIK3CA (0.60) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL16667519 | 0.86 | MTOR (0.50) | MTORPIK3CAPIK3R1PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741896-B2 | Pyrazolopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741896-B2 | Pyrazolopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20120208808-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120208808-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208808-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | PDPK1, PIK3R5, NLRP1 | MTOR 47/4885PIK3CA 7/4885PIK3R1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.